MIKI Shuji | Pre-Clinical Development Department, Development & Medical Affairs Division, GlaxoSmithKline K. K.

スポンサーリンク

概要

関連著者

Hirama Toshiyasu
Clinical Pharmacology Department Development & Medical Affairs Division Glaxosmithkline K. K.
NAKAHARA Norie
Clinical Pharmacology Department, Development & Medical Affairs Division, GlaxoSmithKline K. K.
WAKAMATSU Akira
Clinical Pharmacology Department, Development & Medical Affairs Division, GlaxoSmithKline K. K.
SHIMAMURA Ryutaro
Clinical Research Department 2, Development & Medical Affairs Division, GlaxoSmithKline K. K.
NOHDA Shigeru
Clinical Pharmacology Department, Development & Medical Affairs Division, GlaxoSmithKline K. K.
MIKI Shuji
Pre-Clinical Development Department, Development & Medical Affairs Division, GlaxoSmithKline K. K.
Miki Shuji
Pre-clinical Development Department Development & Medical Affairs Division Glaxosmithkline K. K.
Nakahara Norie
Clinical Pharmacology Department Development & Medical Affairs Division Glaxosmithkline K. K.
Wakamatsu Akira
Clinical Pharmacology Department Development & Medical Affairs Division Glaxosmithkline K. K.
Shimamura Ryutaro
Clinical Research Department 2 Development & Medical Affairs Division Glaxosmithkline K. K.
Nohda Shigeru
Clinical Pharmacology Department Development & Medical Affairs Division Glaxosmithkline K. K.

もっと見る

著作論文

Pharmacokinetics of Ambrisentan, a Novel Drug for Treatment of Pulmonary Arterial Hypertension (PAH), in Japanese Subjects

スポンサーリンク